In patients with neuromuscular disorders, weakness is apparent in the orbicularis oculi, a group of facial muscles that control the eyelids.

TOP INSIGHT
The extraocular muscles that control the movement of the eye are not affected by Duchenne muscular dystrophy.
Using healthy human muscle cell cultures and differentiated human myotubes grown on glass coverslips, the team led by Susan Treves, PhD and Francesco Zorzato, MD, PhD, of the departments of Anaesthesia and Biomedicine at Basel University Hospital, examined the excitation-contraction coupling (ECC) process and calcium homeostasis in the orbicularis oculi, extraocular muscles, and a third muscle group--the quadriceps.
ECC is the process whereby an electrical signal is converted into a chemical signal leading to muscle contraction. They found that ECC machinery and calcium regulation of human orbicularis oculi are more similar to those of quadriceps than of extraocular muscles.
"Although gene expression in orbicularis oculi is quite different from that in quadriceps, the expression of proteins involved in the ECC process is similar in both cell types," the authors note.
The researchers also gained unique insight into the presence and absence of dystrophin, the protein located primarily in muscles used for movement, and utrophin, which shares both structural and functional similarities with dystrophin.
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy in children and primarily targets boys, according to the Centers for Disease Control and Prevention, and it results in the loss of the ability to walk between ages 7 and 13 years, and death in the teens or 20s. DMD is caused by a defective gene for dystrophin.
The authors note that dystrophin and utrophin may share distinct binding partners since their subcellular distribution, at least in myotubes, is different. Dystrophin has a punctate membrane distribution, whereas utrophin has a patchy more filamentous distribution concentrated within specific subcellular domains. Also promising, dystrophin-deficient mdx mouse studies show that utrophin can functionally compensate in vivo for the lack of dystrophin. "This supports current strategies aimed at modulating utrophin expression in the therapy for Duchenne muscular dystrophy," the authors conclude.
Source-Eurekalert
MEDINDIA




Email








